BIOTRON LIMITED (ASX: BIT)

Company Profile: BIOTRON LIMITED (ASX: BIT) – The company is under health care sector and is engaged into clinical trials, research and commercialisation of a number of anti-viral (HCV and HIV) drugs developed from biomedical projects researched at the John Curtin School of Medical Research. The company was listed in 2001 under the Pharmaceuticals, Biotechnology & Life Sciences category, and the headquarter is situated in Hunter Street, Sydney, Australia.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report